p53 alterations in oesophageal cancer: Association with clinicopathological features, risk factors, and survival

Journal of Clinical Pathology - Molecular Pathology

Volumn 51, Issue 2, 1998, Pages 71-79

  Casson, A G ^a   Tammemagi, M ^b   Eskandarian, S ^c   Redston, M ^c   McLaughlin, J ^d   Ozcelik, H ^c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d Institut national du cancer du Canada   (Canada)

Author keywords

Oesophageal cancer; P53; Prognosis

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0031812661     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.51.2.71     Document Type: Article

References (50)

1. DeVesa SS, Blot WJ, Stone BJ, et al. Recent cancer trends in the United States. J Natl Cancer 1995;87:175-82.
2. Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 1996;7:322-7.
3. Greenblatt MS, Bennett W P, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
4. Hollstein M, Shomer B, Greenblatt, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996;24:141-6.
5. Hollstein MC, Metcalf RA, Welsh JA, et al. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958-61.
6. Casson AG, Mukhopadhyay T, Cleary KR, et al. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991;51:4495-9.
7. Bennett WP, Hollstein MC, He A, et al. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene 1991;6:1779-84.
8. Bennett WP, Hollstein MC, Metcalf RA, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992;52:6092-7.
9. Jankowshi J, Coghill G, Hopwood D, et al. Oncogenes and onco-suppressor gene in adenocarcinoma of the esophagus. Gut 1992;33:1033-8.
10. Gao H, Wang L-D, Zhou Q, et al. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Cancer Res 1994;54:4342-6.
11. Neshat K, Sanchez CA, Galipeau PC, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-95.
12. Hamelin R, Flejou J-F, Muzeau F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994;107:1012-18.
13. Liang Y-Y, Esteve A, Maretl-Planche G, et al. p53 mutations in esophageal tumors from high-incidence areas of China. Int J Cancer 1995;61:611-14.
14. Galiana C, Lozano J-C, Bancel B, et al. High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. Mol Carcinog 1995;14: 286-93.
15. Gleeson CM, Sloan JM, McGuigan JA, et al. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 1995;55: 3406-11.
16. Campomenosi P, Conio M, Bogliolo M, et al. p53 is frequently mutated in Barrett's metaplasia of the intestinal type. Cancer Epidemiol Biomarkers Prevent 1996;5:559-65.
17. Huang Y, Meltzer SJ, Yin J, et al. Altered messenger RNA and unique mutational profiles of p53 and Rh in human esophageal carcinomas. Cancer Res 1993;53:1889-94.
18. Sorsdahl K, Casson AG, Troster M, et al. p53 and ras gene expression in human esophageal cancer and Barrett's epithelium: a prospective study. Cancer Detect Prevent 1994;18:179-85.
19. Sasano H, Miyazaki S, Goukon Y, et al. Expression of p53 in human esophageal carcinoma: an immunohistochemical study with correlation to proliferating cell nuclear antigen expression. Hum Pathol 1992;23:1238-43.
20. Younes M., LeBovitz RM, LeChago LV, et al. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993;105: 1637-42.
21. Flejou J-F, Potet F, Le Pelletier F, et al. Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J Clin Pathol 1993;46:330-3.
22. Wang L-D, Hong J-Y, Qiu S-I., et al. Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. Cancer Res 1993;53: 1783-7.
23. Volant A, Nousbaum J-B, Giroux M-A, et al. p53 protein accumulation in oesophageal squamous cell carcinomas and precancerous lesions. J Clin Pathol 1995;48:531-4.
24. 1 SO11 gene products in Barrett's esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol 1996;27:1211-20.
25. Meltzer SJ, Yin J, Huang Y, et al. Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc Natl Acad Sci USA 1991;88:4976-80.
26. Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 1993;53:846-50.
27. Blount PL, Galipeau PC, Sanchez CA, et al. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 1994;54;2292-5
28. Furihata M, Ohtzuki Y, Ogoshi S, et al. Prognostic significance of human papillomavirus genomes (type-16, -18) and aberrant expression of p53 protein in human esophageal cancer. Int J Cancer 1993;54:226-30.
29. Shiyama K, Shiozaki H, Inoue M, et al. Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma. Virchows Archiv A Pathol Anat 1993;422: 271-6.
30. Sarbia M, Porschen R, Borschard F, et al. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218-23.
31. Vijeyasingham R, Darnton SJ, Jenner K, et al. Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. Br J Surg 1994;81: 1623-6.
32. Goukon Y, Sasano H, Nishihira T, et al. p53 overexpression in human esophageal carcinoma: a correlation with tumor DNA ploidy and two parameter flow cytometric study. Anticancer Res 1994;14:1305-12.
33. Wang D-Y, Xiang Y-Y, Tanaka M, et al. High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 1994;74:3089-96.
34. Chanvitan A, Nekarda H, Casson AG. Prognostic value of DNA index, S-phase fraction, and p53 protein accumulation after surgical resection of esophageal squamous cell carcinomas in Thailand. Int J Cancer 1995;63:381-6.
35. Sauter ER, Keller SM, Erner SM. p53 correlates with improved survival in patients with esophageal adenocarcinoma. J Surg Oncol 1995;58:269-73.
36. Casson AG, Kerkvliet N, O'Malley F. Prognostic value of p53 protein in esophageal adenocarcinoma. J Surg Oncol 1995;60:5-11.
37. Coggi G, Bosari S, RoncalliM, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. Cancer 1997;79:425-32.
38. Ozcelik H, Andrulis IL. Multiplex PCR-SSCP for simultaneous screening for mutations in several exons of p53 Biotechnology 1995;18:742-3.
39. Ozcelik H, Mousses S, Andrulis IL. Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations. Clin Cancer Res 1995;1:907-12.
40. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-6.
41. Montesano R, Hollstein M, Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer (Pred Oncol) 1996;69: 225-35.
42. Elledge RM. Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick? J Natl Cancer Inst 1996;88:141-3.
43. Shin DM, Lee JS, Lippman SM, et al. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88: 519-29.
44. Dalquen P, Sauter G, Torhorst J, et al. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol 1996;178:53-8.
45. Munoz N, Victora CG, Crespi M, et al. Hot mate drinking and precancerous lesions of the oesophagus: an endoscopic survey in southern Brazil. Int J Cancer 1987;39:708-9.
46. Rolon PA, Castellsague X, Benz M, et al. Hot and cold mate drinking and esophageal cancer in Paraguay. Cancer Epidemiol Biomarkers Prevent 1995;4:595-605.
47. Launoy G, Milan C, Day NE, et al. Esophageal cancer in France: potential importance of hot alcoholic drinks. Int J Cancer 1997;71:917-23.
48. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-27.
49. McGuire WH. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991;83:154-5.
50. Hermanek P, Sobin LH, eds. TNM classification of malignant tumors. Berlin: Springer-Verlag, 1992.